Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

PT-141 (Bremelanotide) Dosing Protocol: 10 mg Vial — Sexual Dysfunction Guide

PT-141 (bremelanotide) complete dosing protocol for the 10 mg vial — FDA-approved dosing schedule for female sexual arousal disorder and off-label male use.

Go to peptide profileCalculate your dose

Quickstart highlights

PT-141 (bremelanotide, Palatin Technologies) is a cyclic heptapeptide melanocortin receptor agonist.

  • Concentration: 5 mg/mL (10 mg vial + 2 mL bacteriostatic water).
  • At 5 mg/mL: 1 mg = 20 units, 1.75 mg = 35 units (FDA-approved Vyleesi dose), 2 mg = 40 units.
  • Inject 45 minutes before sexual activity; onset 45–90 minutes; duration 4–8 hours.
  • RECONNECT Phase 3: 1.75 mg produced statistically significant improvement in SSEs and sexual distress in premenopausal women.
  • Nausea affects ~40% at 1.75 mg; pre-dose ondansetron 4 mg reduces severity significantly.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1100020As needed (45 min before activity)1 mg — 20 units; test dose to assess nausea tolerance; one 10 mg vial provides 10 test doses
2+175035As needed (45 min before activity)1.75 mg — 35 units (FDA-approved Vyleesi dose for FSIAD); maximum recommended dose
alt200040As needed2 mg — 40 units; off-label higher dose used in male protocols; not FDA-approved for men

Gradual approach

WeekDose (µg)UnitsNotes
1-2500100.5 mg trial dose — 10 units; minimal nausea risk; assess response before advancing to therapeutic dose

Reconstitution steps

  1. Draw 2 mL bacteriostatic water; inject slowly down the vial wall.
  2. Swirl gently until lyophilized powder dissolves; do not shake.
  3. Final concentration: 5 mg/mL (10 mg / 2 mL). At 5 mg/mL: 1 mg = 20 units, 1.75 mg = 35 units.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

monthly-week plan

  • 1 vial
  • 10 syringes
  • 2 mL bac water
  • 10 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Restore sexual desire and arousal through melanocortin MC4R activation in the central nervous system using as-needed PT-141 subcutaneous injection 45 minutes before sexual activity, at the FDA-approved 1.75 mg dose for women or off-label 1–2 mg for men.

Off-cycle: As-needed, not cycled — use when desired, not to exceed 1 dose per 24 hours and not more than 8 uses per month per FDA guidelines.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 5 mg/mL: refrigerate 2–8 °C; use within 28 days. One 10 mg vial provides approximately 5–10 as-needed doses depending on dose used.

Injection & tracking tips

  • Inject subcutaneously in the abdomen or outer thigh 45 minutes before anticipated sexual activity — onset of arousal effects typically occurs within 45–90 minutes.
  • Nausea is the most common side effect (40% of patients at 1.75 mg); taking a low-fat meal before injection and having anti-nausea medication (ondansetron 4 mg) available significantly reduces severity.
  • Do not exceed one injection per 24 hours; transient blood pressure elevation occurs immediately post-injection in some individuals — avoid if uncontrolled hypertension.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Rate sexual desire and arousal response 0–10 subjectively 1 hour after injection to calibrate dose.
  • Track nausea severity (0–10) and duration after each injection.
  • Record blood pressure before and 30 minutes after injection for the first 3 uses if any cardiovascular history.
Log your cycle in the calculator →

How this works & references

PT-141 (bremelanotide, Palatin Technologies) is a cyclic heptapeptide melanocortin receptor agonist. Unlike PDE5 inhibitors (sildenafil, tadalafil), PT-141 acts centrally rather than vascularly: it binds MC4 receptors in the hypothalamic medial preoptic area (mPOA) and activates dopaminergic pathways, increasing sexual motivation and arousal independently of genital blood flow. In the Phase 3 RECONNECT trial (NCT02333344, n=1,267 women), 1.75 mg PT-141 produced a 0.5-point improvement in satisfying sexual events per month and significantly improved Female Sexual Distress Scale scores versus placebo. FDA-approved as Vyleesi for HSDD/FSIAD in premenopausal women in 2019.

Sources

Frequently asked questions

Is PT-141 approved for men?
PT-141 is FDA-approved only for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) / Female Sexual Interest and Arousal Disorder (FSIAD) as Vyleesi. Off-label use in men with sexual dysfunction is practiced, with some small studies showing efficacy for erectile dysfunction and hypoactive desire in men at 1–2 mg doses.
How do I minimize nausea from PT-141?
Four strategies: (1) Start at a 1 mg test dose rather than 1.75 mg; (2) Eat a low-fat meal 1 hour before injection; (3) Take ondansetron (Zofran) 4 mg 30 minutes before injection; (4) Inject in the abdomen rather than the thigh — slower abdominal absorption may reduce peak plasma concentration. Nausea typically peaks at 30–60 minutes and resolves within 3 hours.
How is PT-141 different from Addyi (flibanserin)?
Both treat HSDD in women, but via different mechanisms: Addyi (flibanserin) is a daily oral 5-HT1A agonist/5-HT2A antagonist acting on serotonin-dopamine balance; PT-141 is an as-needed subcutaneous melanocortin agonist acting acutely on MC4R-mediated dopamine arousal. PT-141 is preferred for patients who need flexible, event-driven dosing.
Can PT-141 cause skin darkening like Melanotan II?
PT-141 activates MC4R (brain) with relatively less MC1R (skin melanogenesis) stimulation compared to Melanotan II. Mild skin pigmentation changes with repeated use are possible but significantly less than with Melanotan II. The FDA-approved dose (1.75 mg as-needed monthly) has not produced clinically significant skin darkening in trials.
How many doses does a 10 mg vial provide?
At 1.75 mg per dose: 10 mg ÷ 1.75 mg = 5.7 doses. At 1 mg per dose: 10 doses. A single 10 mg vial typically provides 5–8 as-needed uses. At the FDA-recommended maximum of 8 uses/month, one vial covers approximately one month of use at the 1.25 mg average dose.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →